南财智讯11月7日电，昊海生科公告，公司于2025年11月7日召开第六届董事会第五次会议，审议通过了 《关于使用暂时闲置募集资金进行现金管理的议案》，同意使用不超过人民币3.00亿元的暂时闲置募集 资金进行现金管理，投资安全性高、流动性好、有保本约定的投资产品（包括但不限于协定存款、通知 存款、定期存款、大额存单、收益凭证等）。该事项自董事会审议通过之日起12个月内有效，资金在额 度范围内可滚动使用。公司强调，本次现金管理不会影响募集资金投资项目进度和公司正常生产经营。 ...

Investment Rating - The investment rating for the company is "Buy" with a maintained rating [6][17]. Core Views - The company has experienced a decline in revenue and net profit in the first three quarters of 2025, with revenue at 1.899 billion yuan, down 8.47% year-on-year, and net profit at 305 million yuan, down 10.63% year-on-year [1][2]. - The decrease in profit is attributed to an increase in VAT from 3% to 13% for products produced by its subsidiary, leading to a decline in revenue [2]. - The company is focusing on multi-level development in the medical beauty sector and accelerating the localization of the ophthalmic industry through self-research and investment integration [2][4]. Financial Performance - In the first three quarters of 2025, the company's gross margin was 70.39%, and the net margin was 15.51%, both remaining relatively stable year-on-year [3]. - The sales expense ratio increased by 2.97 percentage points to 31.62%, while the management expense ratio rose by 1.36 percentage points to 17.04% [3]. - The company’s R&D expense ratio decreased by 1.22 percentage points to 7.85% [3]. Product Development and Market Strategy - The company is actively developing new products, with significant advancements in clinical trials for its enhanced water-light injection products and high-permeability scleral lenses [3]. - The marketing strategy is being adjusted to enhance market share, utilizing a diverse range of hyaluronic acid products with differentiated effects and pricing [4]. - The company aims to optimize its sales structure to compensate for the loss of gross profit due to declining sales prices in the ophthalmic sector [2][4]. Revenue and Profit Forecast - Revenue forecasts for 2025-2027 are adjusted to 2.763 billion yuan, 3.006 billion yuan, and 3.287 billion yuan, respectively, reflecting a downward revision due to insufficient domestic consumption and price competition [4]. - The projected net profit for the same period is 423 million yuan, 473 million yuan, and 526 million yuan, respectively [4].

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on November 6, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent on buybacks [1]. Group 1: Buyback Details - China Feihe (06186) repurchased 6.806 million shares for a total of 29.4298 million yuan, representing 0.746% of its total share capital [2]. - Kexin Pharmaceutical-B (02171) repurchased 1.734 million shares for 26.3078 million yuan, accounting for 0.380% of its total share capital [2]. - COSCO Shipping Holdings (01919) repurchased 1.53 million shares for 20.9869 million yuan, which is 0.409% of its total share capital [2]. Group 2: Other Notable Buybacks - Gushengtang (02273) repurchased 493,500 shares for 13.7699 million yuan, representing 3.435% of its total share capital [2]. - China Petroleum & Chemical Corporation (00386) repurchased 2.398 million shares for 10.1066 million yuan, which is 0.100% of its total share capital [2]. - Lianyi Technology-W (09959) repurchased 2.38 million shares for 7.4745 million yuan, accounting for 4.298% of its total share capital [2]. Group 3: Additional Companies - Other companies that conducted buybacks include: - Ruisheng Technology (02018) with 165,000 shares repurchased for 6.5033 million yuan [2]. - MGM China (02282) with 400,000 shares repurchased for 6.3701 million yuan [2]. - Huajian Medical (01931) with 922,000 shares repurchased for 5.9985 million yuan [2]. Group 4: Smaller Buybacks - Companies with smaller buyback amounts include: - Yidian Cloud (02416) with 130,000 shares repurchased for 264,000 yuan [3]. - International Home Retail (01373) with 150,000 shares repurchased for 118,500 yuan [3]. - Mobi Development (00947) with 70,000 shares repurchased for 1.167 million yuan [3].

Core Viewpoint - Haohai Biological Technology has been actively repurchasing its shares, indicating a strategy to support its stock price amid declining performance metrics in the medical aesthetics sector [1][4]. Share Buyback Activity - The company spent HKD 805,700 to repurchase 29,600 shares on November 5, marking the third consecutive trading day of buybacks in November [1]. - In total, Haohai has conducted 23 share buybacks this year, with 11 in the first half and 12 in the second half [1]. - The share buybacks in the second half were divided into two phases: the first from September 15 to September 24, and the second from October 27 to November 5 [1]. Financial Performance - For Q3 2025, the company reported revenue of CNY 594 million, a year-on-year decline of 11.29%, and a net profit of CNY 93.58 million, down 11.39% [4]. - Year-to-date revenue for the first three quarters was CNY 1.899 billion, down 8.47%, with a net profit of CNY 305 million, a decrease of 10.63% [4]. - The decline in revenue is attributed to insufficient domestic consumer demand, intensified industry price competition, and tax rate adjustments [4]. Business Segment Performance - The medical aesthetics segment generated CNY 575 million, accounting for 44.35% of total revenue, with hyaluronic acid products contributing CNY 347 million, down 16.80% [5]. - The epidermal growth factor products saw revenue of CNY 92.38 million, reflecting a growth of 13.73% [5]. Market Position and Valuation - Haohai's current PE (TTM) ratio is 14.82, below the industry average of 20, indicating potential undervaluation [3]. - Despite the stock price decline, the company maintains a net asset value of HKD 26.93 per share, providing an arbitrage opportunity for investors [7]. - Since August 20, 2023, the proportion of shares held by Hong Kong Stock Connect investors has increased from 30.35% to 35.78% [7]. Strategic Focus on Botulinum Toxin - The company has invested USD 31 million in Eirion to develop various botulinum toxin products, aiming to capture a share of the growing market [9]. - The medical aesthetics injection market is dominated by hyaluronic acid and botulinum toxin, which together account for 65% of the market [10]. - The domestic penetration rate for botulinum toxin is significantly lower than in mature markets, suggesting substantial growth potential [12]. Future Outlook - Despite current performance challenges, the company's ongoing development in the botulinum toxin sector may provide a pathway for recovery [14]. - The collaboration with Eirion is expected to yield new products that could enhance market presence and profitability in the future [14].

Core Viewpoint - Haohai Biological Technology has been actively repurchasing its shares, indicating a strategy to support its stock price amid declining performance metrics in the medical aesthetics sector [1][4]. Share Buyback Activity - The company spent HKD 805,700 to repurchase 29,600 shares on November 5, marking the third consecutive trading day of buybacks in November [1]. - In total, Haohai has conducted 23 share buybacks this year, with 11 in the first half and 12 in the second half [1]. - The second phase of buybacks occurred from October 27 to November 5, following an initial phase from September 15 to September 24 [1]. Financial Performance - For Q3 2025, the company reported revenue of CNY 594 million, a year-on-year decline of 11.29%, and a net profit of CNY 93.58 million, down 11.39% [4]. - Year-to-date revenue for the first three quarters was CNY 1.899 billion, down 8.47%, with net profit decreasing by 10.63% to CNY 305 million [4]. - The decline in revenue is attributed to insufficient domestic consumer demand, intensified industry price competition, and tax rate adjustments [4]. Business Segment Analysis - The medical aesthetics segment generated CNY 575 million in revenue, accounting for 44.35% of total revenue, with hyaluronic acid products contributing CNY 347 million, down 16.80% [4][6]. - The epidermal growth factor products saw a revenue increase of 13.73% to CNY 92.38 million [4][6]. Market Position and Valuation - Haohai's current PE (TTM) ratio stands at 14.82, below the industry average of 20 [3]. - Despite the declining stock price, the company maintains a net asset value of HKD 26.93 per share, providing potential profit opportunities for investors [8]. Strategic Focus on Botulinum Toxin - The company has entered a partnership with Eirion to develop botulinum toxin products, aiming to capture a share of the growing market [10][15]. - The botulinum toxin market is dominated by foreign brands, but there is significant room for growth in China, where the penetration rate is currently low compared to mature markets like the U.S. [12][13]. Industry Trends - The medical aesthetics market is experiencing a shift, with hyaluronic acid and botulinum toxin being the leading materials, comprising 98% of the injection market [10]. - The domestic market for collagen is growing rapidly, with a projected compound annual growth rate of 41.45% from 2023 to 2027 [11].

Core Viewpoint - Haohai Biological Technology has been actively repurchasing its shares, indicating a strategy to support its stock price amid declining performance metrics in the medical aesthetics sector [1][4]. Share Buyback Activity - The company spent HKD 805,700 to repurchase 29,600 shares on November 5, marking the third consecutive trading day of buybacks in November [1]. - In total, Haohai has conducted 23 share repurchase operations this year, with 11 in the first half and 12 in the second half [1]. - The share buybacks are segmented into two phases: the first from September 15 to September 24, and the second from October 27 to November 5 [1]. Financial Performance - For Q3 2025, the company reported revenue of CNY 594 million, a year-on-year decline of 11.29%, and a net profit of CNY 93.58 million, down 11.39% [4]. - Year-to-date revenue for the first three quarters was CNY 1.899 billion, down 8.47%, with net profit decreasing by 10.63% to CNY 305 million [4]. - The decline in revenue is attributed to insufficient domestic consumer demand, intensified industry price competition, and tax rate adjustments [4]. Business Segment Analysis - The medical aesthetics segment generated CNY 575 million in revenue, accounting for 44.35% of total revenue, with hyaluronic acid products contributing CNY 347 million, down 16.80% [4][6]. - The epidermal growth factor products saw a revenue increase of 13.73% to CNY 92.38 million [4][6]. Market Position and Valuation - Haohai's current PE (TTM) ratio stands at 14.82, below the industry average of 20 [3]. - Despite the declining stock price, the company maintains a net asset value of HKD 26.93 per share, providing potential profit opportunities for investors [8]. Strategic Focus on Botulinum Toxin - The company has entered a partnership with Eirion to develop botulinum toxin products, aiming to capture a share of the growing market [10][15]. - The botulinum toxin market is seen as a promising area for growth, with significant potential for market penetration in China compared to more mature markets like the U.S. [12][13]. Industry Trends - The medical aesthetics market is currently experiencing a transition, with hyaluronic acid and botulinum toxin being the leading products [10][11]. - The domestic market for botulinum toxin is still developing, with a low penetration rate compared to the U.S., indicating room for growth [13][14].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年11月6日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 第 2 頁 共 8 頁 v 1.3.0 | | | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | | 說明 | | A 股（上海證券交易所科創板，股份代號：688366） | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫 ...

智通财经APP讯，昊海生物科技(06826)发布公告，于2025年11月6日该公司斥资74.69万港元回购2.71万 股，回购价格为每股27.52-27.58港元。 ...

格隆汇11月6日丨昊海生物科技(06826.HK)发布公告，2025年11月6日耗资74.69万港元回购2.71万股，回 购价格每股27.52-27.58港元。 ...

Core Viewpoint - Haohai Biological Technology (06826) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Buyback Details - The company plans to repurchase 27,100 shares at a total cost of HKD 746,900 [1] - The buyback price ranges from HKD 27.52 to HKD 27.58 per share [1]